

Artificial Intelligence in Drug Discovery

Drug Discovery Series

Editor-in-chief

David Thurston, *King's College London, UK*

Series editors:

David Fox, *Vulpine Science and Learning, UK*

Ana Martinez, *Centro de Investigaciones Biologicas-CSIC, Spain*

David Rotella, *Montclair State University, USA*

Hong Shen, *Roche Innovation Center Shanghai, China*

Editorial advisor:

Ian Storer, *AstraZeneca, UK*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2
- 4: Accounts in Drug Discovery
- 5: New Frontiers in Chemical Biology
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration
- 8: G Protein-Coupled Receptors
- 9: Pharmaceutical Process Development
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets
- 19: Kinase Drug Discovery
- 20: Drug Design Strategies: Computational Techniques and Applications
- 21: Designing Multi-Target Drugs
- 22: Nanostructured Biomaterials for Overcoming Biological Barriers
- 23: Physico-Chemical and Computational Approaches to Drug Discovery
- 24: Biomarkers for Traumatic Brain Injury
- 25: Drug Discovery from Natural Products
- 26: Anti-Inflammatory Drug Discovery
- 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules
- 28: Drug Discovery for Psychiatric Disorders
- 29: Organic Chemistry of Drug Degradation
- 30: Computational Approaches to Nuclear Receptors

- 31: Traditional Chinese Medicine
- 32: Successful Strategies for the Discovery of Antiviral Drugs
- 33: Comprehensive Biomarker Discovery and Validation for Clinical Application
- 34: Emerging Drugs and Targets for Parkinson's Disease
- 35: Pain Therapeutics; Current and Future Treatment Paradigms
- 36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology
- 37: Inhibitors of Molecular Chaperones as Therapeutic Agents
- 38: Orphan Drugs and Rare Diseases
- 39: Ion Channel Drug Discovery
- 40: Macrocycles in Drug Discovery
- 41: Human-based Systems for Translational Research
- 42: Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics
- 43: Carbohydrates in Drug Design and Discovery
- 44: Drug Discovery for Schizophrenia
- 45: Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies
- 46: Green Chemistry Strategies for Drug Discovery
- 47: Fragment-Based Drug Discovery
- 48: Epigenetics for Drug Discovery
- 49: New Horizons in Predictive Drug Metabolism and Pharmacokinetics
- 50: Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation
- 51: Nanomedicines: Design, Delivery and Detection
- 52: Synthetic Methods in Drug Discovery: Volume 1
- 53: Synthetic Methods in Drug Discovery: Volume 2
- 54: Drug Transporters: Role and Importance in ADME and Drug Development
- 55: Drug Transporters: Recent Advances and Emerging Technologies
- 56: Allosterism in Drug Discovery
- 57: Anti-aging Drugs: From Basic Research to Clinical Practice
- 58: Antibiotic Drug Discovery: New Targets and Molecular Entities
- 59: Peptide-based Drug Discovery: Challenges and New Therapeutics
- 60: Drug Discovery for Leishmaniasis
- 61: Biophysical Techniques in Drug Discovery
- 62: Acute Brain Impairment Through Stroke: Drug Discovery and Translational Research
- 63: Theranostics and Image Guided Drug Delivery
- 64: Pharmaceutical Formulation: The Science and Technology of Dosage Forms
- 65: Small-molecule Transcription Factor Inhibitors in Oncology
- 66: Therapies for Retinal Degeneration: Targeting Common Processes
- 67: Kinase Drug Discovery: Modern Approaches

- 68: Advances in Nucleic Acid Therapeutics
- 69: MicroRNAs in Diseases and Disorders: Emerging Therapeutic Targets
- 70: Emerging Drugs and Targets for Multiple Sclerosis
- 71: Cytotoxic Payloads for Antibody–Drug Conjugates
- 72: Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls
- 73: Anti-fibrotic Drug Discovery
- 74: Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
- 75: Artificial Intelligence in Drug Discovery

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House,
Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Email: booksales@rsc.org

Visit our website at www.rsc.org/books

Artificial Intelligence in Drug Discovery

Edited by

Nathan Brown

Benevolent AI, UK

Email: nathan.brown@benevolent.ai

Drug Discovery Series No. 75
Print ISBN: 978-1-78801-547-9
PDF ISBN: 978-1-78801-684-1
EPUB ISBN: 978-1-83916-054-7
Print ISSN: 2041-3203
Electronic ISSN: 2041-3211

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2021

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

Whilst this material has been produced with all due care, The Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by The Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of The Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material.

The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 20 7437 8656.

For further information see our web site at www.rsc.org

Printed in the United Kingdom by CPI Group (UK) Ltd, Croydon, CR0 4YY, UK